Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Firms Have ‘Continuous Monitoring’ Burden To Show Product Safety

This article was originally published in The Tan Sheet

Executive Summary

Former FDA supplement programs head Bill Frankos says the industry bears the burden for monitoring product safety in the marketplace because FDA does not have the same vested interest it has for drugs and medical devices stemming from pre-market approval of the products.

You may also be interested in...



Supplement Adverse Event Reports Sprout In Fertile Field Of Social Media

Compliance with FDA regulations on supplement marketers reporting serious adverse events means scrutinizing all information about a product on social media pages the same way a firm would comments that consumers or other parties submit by using contact information on product labeling.

FDA To Fill Frankos' Shoes As Major Dietary Supplement Initiatives Pend

The successor to Vasilios "Bill" Frankos, FDA's director of Dietary Supplement Programs, will face a full plate of imminent and ongoing regulatory issues

AER Label Guidance Holds To Requiring Full Addresses For OTCs, Supplements

FDA is extending the deadline for serious adverse event labeling requirements for OTC drugs and dietary supplements until January 2010 because it has yet to finalize its guidance to comply with those regulations

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel